|
|
 |
|
Viewing report
|
|
 |
 |
Emerging pharmaceutical markets Argentina and Mexico
Datamonitor, March 2008, Pages: 106
CHAPTER 1 EXECUTIVE SUMMARY 4 Scope of the report 4 Key findings 4 Argentina 4 Mexico 5 IMS caveat 6 CHAPTER 2 THE PHARMACEUTICAL MARKET IN ARGENTINA 11 Argentina has stable macroeconomic factors, some of which must be strengthened 11 A growing pharmaceutical market dominated by branded generics 12 Demographic trends in Argentina 13 Disease burden in Argentina 14 Socioeconomic environment in Argentina 15 Political climate in Argentina - stable 15 GDP has been growing after the economic crisis of 2001 16 Regional differences - the fight for equality continues 17 Mercosur established free trade between the countries involved 18 Corporate environment in Argentina 19 Foreign direct investment in Argentina is modest 19 Taxation system in Argentina 19 The healthcare system in Argentina 21 Healthcare expenditure in Argentina is high 23 The public sector is decentralized 23 Social health insurance system is fragmented 24 The private sector covers a minority of the population 25 The hospital capacity within the public sector has declined while the private sector has been growing 25 Regulatory issues in Argentina 26 IP protection has improved but is still inadequate 26 A significant effort has been made to reduce the patent backlog in Argentina 27 Registration of drugs in Argentina is a straight forward procedure 28 Advertising of pharmaceuticals is strictly controlled 28 Import of pharmaceuticals has been facilitated by Mercosur agreement 29 Drug counterfeiting has been reduced by a number of measures 29 Pricing and reimbursement of pharmaceuticals in Argentina 30 Pricing of pharmaceuticals in Argentina 30 The Generics Law, resulted in lower prices and increased access to pharmaceuticals 30 Antiretroviral therapy prices were decreased 31 Reimbursement of pharmaceuticals in Argentina 32 Remediar program, introduced in 2002, increased drug access to the poor 33 Pharmaceutical market dynamics in Argentina 34 Branded generics dominate the Argentinean market 35 Top three distributors dominate while retail pharmacy chains are expanding 37 Top manufacturers on the Argentinean retail market 38 Top ATC groups by sales value on the Argentinean retail market 39 Top brands on the Argentinean retail market 42 Import and export of pharmaceuticals - demand for foreign drugs remains high 43 Major foreign pharmaceutical companies in Argentina 43 Pfizer 43 Bayer 44 Roche 44 Major domestic pharmaceutical companies in Argentina 44 Roemmers 45 Bagó - collaboration and geographical expansion are driving growth 45 Phoenix 46 Clinical trials in Argentina - an underused opportunity 47 CHAPTER 3 THE PHARMACEUTICAL MARKET IN MEXICO 51 Growth of the Mexican economy and strengthened intellectual property rights are boosting pharma industry 51 The Mexican pharmaceutical market is dominated by foreign companies and is attracting a lot of clinical research 52 Demographic trends in Mexico 53 Disease burden in Mexico 54 Socioeconomic environment in Mexico 55 Political climate in Mexico 55 GDP has increased since the introduction of NAFTA 56 Regional differences - some rural areas are in extreme poverty 57 NAFTA eliminated tariffs between the US, Canada and Mexico, and boosted the Mexican economy 57 Corporate environment in Mexico 58 Taxation system in Mexico 58 Foreign direct investment in Mexico was boosted by NAFTA agreement 58 The healthcare system in Mexico 60 Healthcare system reforms in Mexico - the national health system aims to provide choice of healthcare provider 60 Healthcare expenditure in Mexico is low 62 The social security sector 62 Governmental services headed by the Ministry of Health are designed to offer coverage to the poor and uninsured 63 Only a small proportion of the population has private health insurance 63 Regulatory issues in Mexico 64 Intellectual property (IP) protection has significantly improved 64 Registration of drugs in Mexico is simple 65 Physicians play an important role in drug choices 66 Import of pharmaceuticals in Mexico is facilitated by NAFTA 66 Counterfeit drugs are a persistent problem in Mexico 67 Pricing and reimbursement of pharmaceuticals in Mexico 67 Pricing of pharmaceuticals in Mexico 67 Reimbursement in Mexico 69 Pharmaceutical market dynamics in Mexico 73 Mexico classifies generics into three segments 74 Market growth is driven mainly by growing preference and demand for high-value products and not by volume growth 74 Distribution of pharmaceuticals in Mexico is dominated by two distributors 75 Pharmacies selling cheap pharmaceuticals are very popular in Mexico 75 Top pharmaceutical companies in Mexico-multinationals dominate 76 Top ATC groups by sales value on the Mexican retail market 77 Top brands on the Mexican retail market 80 Import and export of pharmaceuticals have increased since NAFTA came into place 81 Major foreign pharmaceutical companies in Mexico 81 Sanofi-Aventis 82 Pfizer 82 AstraZeneca 82 Major domestic pharmaceutical companies in Mexico 83 Senosiain 83 Clinical trials in Mexico - an attractive opportunity for US companies 84 CHAPTER 4 BIBLIOGRAPHY 86 Publications and online articles 86 Datamonitor resources 96 Glossary of Terms 97 List of Tables Table 1: Demographic indicators for Argentina, 2005 13 Table 2: Average annual growth rate of GDP and exports in Argentina, 1998-2010 (%), 16 Table 3: Key economic indicators for Argentina, 1986-2006 17 Table 4: Health expenditure indicators in Argentina, 2004 23 Table 5: Density of healthcare workers and hospital capacity in Argentina, 1998 26 Table 6: Argentina - Growth of pharmaceutical market in terms of sales volume, 2003-06 35 Table 7: Argentina - Average cost of unit sold, 2003-06 35 Table 8: Branded generics dominate the Argentinean pharmaceutical market, 2006 36 Table 9: Top 15 drug manufacturers in Argentina, 2006 38 Table 10: Market segmentation in Argentina according to ATC groups, 2006 39 Table 11: Top 15 brands in Argentina, 2006 42 Table 12: Key demographic indicators for Mexico, 2005 53 Table 13: Mexico -average annual growth rates of GDP and exports (%), 1986-2010 56 Table 14: Key economic indicators for Mexico, 1986-2006 57 Table 15: Health expenditure indicators in Mexico, 2004 62 Table 16: Growth of the Mexican market in terms of sales volume, 2003-06 74 Table 17: Average cost of unit sold, 2003-06 75 Table 18: Top 15 drug manufacturers in Mexico in 2006 76 Table 19: Growth of ATC group split in the Mexican market, 2006 77 Table 20: Top 15 brands in 2006 in Mexico 80 List of Figures Figure 1: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical industry in Argentina, 2008 11 Figure 2: Pharmaceutical market dynamics in Argentina, 2008 12 Figure 3: Structure of health system financing and provision in Argentina 22 Figure 4: The size of the Argentinean retail pharmaceutical market, 2002-06 34 Figure 5: Sales growth and CAGR for the top ATC groups in Argentina 40 Figure 6: The relative market share for each ATC group in Argentina is very similar to the six major markets 41 Figure 7: Clinical trial protocols assessed and approved, 1994-2006 48 Figure 8: Multinational pharmaceutical companies sponsor the majority of clinical research in Argentina 49 Figure 9: Advantages and disadvantages of carrying out clinical trials in Argentina 50 Figure 10: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical industry in Mexico 51 Figure 11: Pharmaceutical market dynamics in Mexico 52 Figure 12: The three pricing regulations in Mexico 69 Figure 13: Decision process for listing pharmaceuticals on the Basic Formulary and the Catalogue of Inputs 71 Figure 14: The size of the Mexican retail pharmaceutical market, 2002-06 73 Figure 15: Sales growth and CAGR for the top ATC groups in Mexico, 2006 78 Figure 16: The relative market shares of each ATC groups are very similar between Mexico and the six major markets 79 Figure 17: Advantages and disadvantages of carrying out clinical trials in Mexico 85
Customers who bought this item also bought
The Pharmaceutical Market: Argentina
The Pharmaceutical Market: Mexico
Mexico Pharmaceuticals and Healthcare Report Q4 2008
Argentina Pharmaceuticals and Healthcare Report Q2 2009
Mexico Pharmaceuticals and Healthcare Report Q2 2008
Argentina Pharmaceuticals and Healthcare Report Q3 2008
Argentina Pharmaceuticals and Healthcare Report Q1 2010
Mexico Pharmaceuticals and Healthcare Report Q1 2009
Pharmaceutical Industry in Mexico
Mexico Pharmaceuticals and Healthcare Report Q3 2008
Executive Report on Strategies in Mexico
Mexico Pharmaceuticals and Healthcare Report Q1 2008
|
 |
|
|